

Proceeding Paper

Synthesis, Spectral Characteristics, and Molecular Docking Studies of 2-(2,4-Dichlorophenoxy)-N-(2,2,2-Trichloro-1-(3-Arylthioureido)Ethyl)Acetamide[†]

Elizaveta R. Lominoga, Pavlo V. Zadorozhnii *, Valeria V. Kobets, Vadym V. Kiselev and Aleksandr V. Kharchenko

Department of Pharmacy and Technology of Organic Substances, Ukrainian State University of Chemical Technology, Gagarin Ave 8, 49005 Dnipro, Ukraine; elizaveta.romanovna@gmail.com (E.R.L.); lv705757@gmail.com (V.V.K.); vadvitkis@gmail.com (V.V.K.); pashaalhimik@i.ua (A.V.K.)

* Correspondence: torfp@i.ua; Tel.: +38-067-425-2710

† Presented at the 4th International Electronic Conference on Applied Sciences, 27 Oct–10 Nov 2023;

Available online: <https://asec2023.sciforum.net/>.

Abstract: 2-(2,4-Dichlorophenoxy)acetic acid and its derivatives are promising anti-inflammatory agents capable of selectively inhibiting the COX-2 enzyme. In this paper, we report on the synthesis of a series of new derivatives of 2-(2,4-dichlorophenoxy)acetic acid - 2-(2,4-dichlorophenoxy)-N-(2,2,2-trichloro-1-(3-arylthioureido)ethyl)acetamides. The method for the synthesis of these compounds is based on the addition of aromatic amines to 2-(2,4-dichlorophenoxy)-N-(2,2,2-trichloro-1-isothiocyanatoethyl)acetamide. Target products were obtained in 58-72% yield. The structure of the obtained compounds was reliably proven by ¹H and ¹³C NMR spectroscopy data. In order to establish the prospects of the synthesized compounds as potential anti-inflammatory agents, we carried out molecular docking studies with COX-2. Molecular docking was carried out using the AutoDock Vina program based on the PyRx 0.8 platform. The preparation of the enzyme structure (PDB ID: 4M11, *Mus musculus*) and structures of potential inhibitors was carried out using the Chimera 1.14 and ArgusLab 4.0.1 programs, respectively. The conformation corresponding to the lowest energy was chosen as the most likely binding position. According to the results of molecular docking, the structures of the synthesized compounds effectively interact with the active site of COX-2 and surpass 2-(2,4-dichlorophenoxy)acetic acid in terms of the strength of the complex formed with this enzyme.

Keywords: 2-(2,4-dichlorophenoxy)acetic acid; synthesis; anti-inflammatory; molecular docking; COX-2; thiourea

Citation: Lominoga, E.R.; Zadorozhnii, P.V.; Kobets, V.V.; Kiselev, V.V.; Kharchenko, A.V. Synthesis, Spectral Characteristics, and Molecular Docking Studies of 2-(2,4-Dichlorophenoxy)-N-(2,2,2-Trichloro-1-(3-Arylthioureido)Ethyl)Acetamide.

2023, 5, x.

<https://doi.org/10.3390/xxxxx>

Academic Editor(s):

Published: date



Copyright: © 2023 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

2,4-Dichlorophenoxyacetic acid and its derivatives are widely used as biologically active substances. This acid is one of the most widely used herbicides in the world, known by the abbreviation 2,4-D [1]. 2,4-Dichlorophenoxyacetic acid is also of interest to medicine and pharmacy as a COX-2 inhibitor and, as a result, a potential anti-inflammatory agent [2]. Several other substances are also known to have anti-inflammatory activity and contain a 2,4-dichlorophenoxy group as a pharmacophore [3-5]. Alkylamide [6-9] and thiourea [10-12] fragments can also be distinguished among the pharmacophore groups with potential anti-inflammatory activity.

This study has combined all three pharmacophore groups in one molecule to create new and effective anti-inflammatory agents. We have obtained a series of 2-(2,4-dichlorophenoxy)-N-(2,2,2-trichloro-1-(3-arylthioureido)ethyl)acetamides (Figure 1), which differ

from each other by an aryl substituent in the thiourea fragment. The structures of the obtained compounds have been tested *in silico* for their ability to inhibit the COX-2 enzyme.




Figure 1. Structure of the obtained potential COX-2 inhibitors simultaneously containing 2,4-dichlorophenoxy, alkylamide, and thiourea pharmacophore groups.

The resulting compounds may also be promising for other areas of pharmacology and toxicology. For example, effective inhibitors of the GADD34:PP1 holoenzyme complex, such as Salubrinal and Sal003 [13-16], as well as moderate inhibitors of some enzymes of the P450 family [17] and the hERG ion channel [18] are known among their structural analogs. In addition, these compounds are of interest for synthetic organic chemistry as substrates for the preparation of 4*H*-1,3,5-oxadiazine derivatives [19-22].

2. Materials and Methods

2.1. Chemistry

Synthesis of 2-(2,4-dichlorophenoxy)-*N*-(2,2,2-trichloro-1-hydroxyethyl)acetamide (**3**) [23]. Hydroxy derivative **3** was obtained by condensation of chloral hydrate (**1**) with 2,4-dichlorophenoxyacetic acid amide (**2**) according to the procedure described in [24]. White crystals; yield 90%; mp 123-125 °C (MeCN); $R_f = 0.67$. Anal. Calcd (%) for $C_{10}H_8Cl_5NO_3$ (367.43): C, 32.69; H, 2.19; N, 3.81. Found: C, 32.65; H, 2.17; N, 3.85.

Synthesis of 2-(2,4-dichlorophenoxy)-*N*-(2,2,2-trichloro-1-isothiocyanatoethyl)acetamide (**5**). Isothiocyanate (**5**) was obtained through the stage of formation of the intermediate chlorine derivative (**4**) according to the procedure described in [25]. The product could not be isolated from the reaction mixture. Further transformations involving isothiocyanate (**5**) were carried out using its solution.

Synthesis of 2-(2,4-dichlorophenoxy)-*N*-(2,2,2-trichloro-1-(3-arylthioureido)ethyl)acetamides (**7a-h**). A solution of 10 mmol of one of the amines **6a-h** in 10 ml of acetonitrile was added to a mother solution of 10 mmol (4.09 g, theoretical yield) of isothiocyanate **5** in 10 ml of acetonitrile. The mixture was brought to a boil and left for 24 hours. The precipitate formed was filtered, washed with 10 ml of acetonitrile, and purified by recrystallization from acetonitrile or ethanol.

2-(2,4-Dichlorophenoxy)-*N*-(2,2,2-trichloro-1-(3-(2,4-dimethylphenyl)thioureido)ethyl)acetamide (**7a**). Pale yellow crystals; yield 72% (3.92 g); mp 191-193 °C (MeCN); $R_f = 0.71$. 1H NMR: δ 9.89 (s, 1H, NH), 8.89 (d, $J = 7.8$ Hz, 1H, NH), 8.02 (br. s, 1H, NH), 7.57 (s, 1H, $H_{arom.}$), 7.41 (t, $J = 8.8$ Hz, 1H, $H_{arom.}$), 7.33 (d, $J = 8.3$ Hz, 1H, $H_{arom.}$), 7.11-7.00 (m, 4H, $3H_{arom.}+CH$), 4.77 (q, $J = 15.2$ Hz, 2H, CH_2), 2.27 (s, 3H, CH_3), 2.15 (s, 3H, CH_3). ^{13}C NMR: δ 182.0 (C=S), 166.7 (C=O), 152.3, 136.2, 134.5, 134.1, 131.1, 129.4, 128.0, 127.7, 126.9, 125.4, 122.7, 115.8 ($C_{arom.}$), 101.6 (CCl_3), 69.7 (CH), 67.8 (CH_2), 20.6 (CH_3), 17.6 (CH_3). Anal. Calcd (%) for $C_{19}H_{18}Cl_5N_3O_2S$ (529.68): C, 43.08; H, 3.43; N, 7.93. Found: C, 43.05; H, 3.39; N, 7.98.

2-(2,4-Dichlorophenoxy)-*N*-(2,2,2-trichloro-1-(3-(2,5-dimethylphenyl)thioureido)ethyl)acetamide (**7b**). Pale yellow crystals; yield 68% (3.60 g); mp 188-190 °C (MeCN); $R_f = 0.77$. 1H NMR: δ 9.87 (s, 1H, NH), 8.91 (br. s, 1H, NH), 8.06 (br. s, 1H, NH), 7.61 (s, 1H, $H_{arom.}$), 7.42-7.34 (m, 2H, $H_{arom.}$), 7.15 (d, $J = 7.8$ Hz, 1H, $H_{arom.}$), 7.04-7.00 (m, 3H, $2H_{arom.}+CH$), 4.77 (q, $J = 15.6$ Hz, 2H, CH_2), 2.25 (s, 3H, CH_3), 2.14 (s, 3H, CH_3). ^{13}C NMR: δ 181.9 (C=S), 166.7 (C=O), 152.3, 136.5, 135.4, 131.4, 130.4, 129.4, 128.1,

128.0, 127.6, 125.4, 122.6, 115.8 (C_{arom.}), 101.6 (CCl₃), 69.7 (CH), 67.8 (CH₂), 20.5 (CH₃), 17.2 (CH₃). Anal. Calcd (%) for C₁₉H₁₈Cl₅N₃O₂S (529.68): C, 43.08; H, 3.43; N, 7.93. Found: C, 43.12; H, 3.40; N, 7.97.

2-(2,4-Dichlorophenoxy)-N-(2,2,2-trichloro-1-(3-(2-methoxyphenyl)thioureido)ethyl)acetamide (**7c**). Pale yellow crystals; yield 70% (3.72 g); mp 193-195 °C (EtOH); R_f = 0.68. ¹H NMR: δ 9.77 (s, 1H, NH), 8.92 (d, J = 8.8 Hz, 1H, NH), 8.47 (br. s, 1H, NH), 7.85 (br. s, 1H, H_{arom.}), 7.61 (d, J = 2.9 Hz, 1H, H_{arom.}), 7.40-7.34 (m, 2H, H_{arom.}), 7.18 (t, J = 7.3 Hz, 1H, H_{arom.}), 7.07 (d, J = 7.8 Hz, 1H, H_{arom.}), 7.02 (d, J = 9.3 Hz, 1H, H_{arom.}), 6.93 (dd, J = 8.8, 6.9 Hz, 1H, CH), 4.79 (q, J = 15.4 Hz, 2H, CH₂), 3.83 (s, 3H, OCH₃). ¹³C NMR: δ 181.1 (C=S), 166.6 (C=O), 152.3, 151.8, 129.4, 128.0, 127.0, 126.3, 125.9, 125.3, 122.5, 119.9, 115.6, 111.5 (C_{arom.}), 101.3 (CCl₃), 69.5 (CH), 67.5 (CH₂), 55.7 (OCH₃). Anal. Calcd (%) for C₁₈H₁₆Cl₅N₃O₃S (531.65): C, 40.67; H, 3.03; N, 7.90. Found: C, 40.63; H, 2.99; N, 7.94.

N-(1-(3-(4-Acetamidophenyl)thioureido)-2,2,2-trichloroethyl)-2-(2,4-dichlorophenoxy)acetamide (**7d**). Pale yellow crystals; yield 58% (3.41 g); mp 171-173 °C (MeCN); R_f = 0.28. ¹H NMR: δ 9.98 (s, 1H, NH), 9.68 (s, 1H, NH), 8.73 (d, J = 8.8 Hz, 1H, NH), 8.12 (br. s, 1H, NH), 7.60 (s, 1H, H_{arom.}), 7.56 (d, J = 8.3 Hz, 1H, H_{arom.}), 7.37-7.34 (m, 3H, H_{arom.}), 6.76 (d, J = 8.3 Hz, 2H, H_{arom.}), 5.98 (dd, J = 9.3, 8.8 Hz, 1H, CH), 4.77 (q, J = 15.6 Hz, 2H, CH₂), 1.98 (s, 3H, CH₃). ¹³C NMR: δ 180.7 (C=S), 167.6 (C=O), 166.7 (C=O), 152.2, 141.1, 131.3, 129.4, 127.9, 125.3, 124.2, 120.6, 119.3, 114.2 (C_{arom.}), 101.6 (CCl₃), 70.7 (CH), 67.1 (CH₂), 23.8 (CH₃). Anal. Calcd (%) for C₁₉H₁₇Cl₅N₄O₃S (558.68): C, 40.85; H, 3.07; N, 10.03. Found: C, 40.81; H, 3.05; N, 10.06.

Ethyl 4-(3-(2,2,2-trichloro-1-(2-(2,4-dichlorophenoxy)acetamido)ethyl)thioureido)benzoate (**7e**). Pale yellow crystals; yield 67% (3.84 g); mp 195-197 °C (MeCN); R_f = 0.60. ¹H NMR: δ 10.65 (s, 1H, NH), 8.91 (d, J = 8.8 Hz, 1H, NH), 8.53 (d, J = 9.3 Hz, 1H, NH), 7.94 (d, J = 8.8 Hz, 2H, H_{arom.}), 7.77 (d, J = 8.8 Hz, 2H, H_{arom.}), 7.61 (d, J = 2.9 Hz, 1H, H_{arom.}), 7.37-7.33 (m, 2H, H_{arom.}), 7.03 (d, J = 9.3 Hz, 1H, CH), 4.80 (q, J = 15.7 Hz, 2H, CH₂), 4.30 (q, J = 7.3 Hz, 2H, CH₂), 1.31 (t, J = 7.3 Hz, 3H, CH₃). ¹³C NMR: δ 180.5 (C=S), 166.8 (C=O, amide), 165.2 (C=O, ester), 152.3, 143.4, 129.9, 129.4, 128.0, 125.4, 125.3, 122.5, 121.6, 115.6 (C_{arom.}), 101.0 (CCl₃), 69.1 (CH), 67.5 (CH₂), 60.6, 14.2 (ethyl). Anal. Calcd (%) for C₂₀H₁₈Cl₅N₃O₄S (573.69): C, 41.87; H, 3.16; N, 7.32. Found: C, 41.85; H, 3.12; N, 7.37.

2-(2,4-Dichlorophenoxy)-N-(2,2,2-trichloro-1-(3-(2-chlorophenyl)thioureido)ethyl)acetamide (**7f**). Pale yellow crystals; yield 69% (3.70 g); mp 196-198 °C (MeCN); R_f = 0.63. ¹H NMR: δ 9.69 (s, 1H, NH), 8.98 (d, J = 8.8 Hz, 1H, NH), 8.60 (d, J = 9.3 Hz, 1H, NH), 7.68 (d, J = 7.8 Hz, 1H, H_{arom.}), 7.61 (d, J = 2.5 Hz, 1H, H_{arom.}), 7.53 (d, J = 8.3 Hz, 1H, H_{arom.}), 7.37-7.34 (m, 3H, H_{arom.}), 7.29-7.25 (m, 1H, H_{arom.}), 7.03 (d, J = 8.8 Hz, 1H, CH), 4.81 (q, J = 15.7 Hz, 2H, CH₂). ¹³C NMR: δ 182.4 (C=S), 166.7 (C=O), 152.3, 135.8, 129.5, 129.4, 129.3, 129.2, 128.0, 127.7, 127.2, 125.3, 122.5, 115.6 (C_{arom.}), 101.2 (CCl₃), 69.6 (CH), 67.5 (CH₂). Anal. Calcd (%) for C₁₇H₁₃Cl₆N₃O₂S (536.07): C, 38.09; H, 2.44; N, 7.84. Found: C, 38.12; H, 2.40; N, 7.88.

N-(1-(3-(4-Bromophenyl)thioureido)-2,2,2-trichloroethyl)-2-(2,4-dichlorophenoxy)acetamide (**7g**). Pale yellow crystals; yield 72% (4.30 g); mp 186-188 °C (MeCN); R_f = 0.75. ¹H NMR: δ 10.36 (s, 1H, NH), 8.86 (d, J = 8.3 Hz, 1H, NH), 8.34 (d, J = 9.3 Hz, 1H, NH), 7.61 (d, J = 2.4 Hz, 1H, H_{arom.}), 7.55 (d, J = 8.8 Hz, 2H, H_{arom.}), 7.50 (d, J = 8.8 Hz, 2H, H_{arom.}), 7.37-7.32 (m, 2H, H_{arom.}), 7.03 (d, J = 8.3 Hz, 1H, CH), 4.80 (q, J = 15.2 Hz, 2H, CH₂). ¹³C NMR: δ 180.8 (C=S), 166.7 (C=O), 152.3, 138.2, 131.5, 129.4, 128.0, 125.4, 125.1, 122.6, 116.9, 115.7 (C_{arom.}), 101.2 (CCl₃), 69.3 (CH), 67.6 (CH₂). Anal. Calcd (%) for C₁₇H₁₃BrCl₅N₃O₂S (580.52): C, 35.17; H, 2.26; N, 7.24. Found: C, 35.13; H, 2.24; N, 7.28.

2-(2,4-Dichlorophenoxy)-N-(2,2,2-trichloro-1-(3-(naphthalen-1-yl)thioureido)ethyl)acetamide (**7h**). Pale yellow crystals; yield 64% (3.53 g); mp 205-207 °C (MeCN); R_f = 0.69. ¹H NMR: δ 10.44 (s, 1H, NH), 8.89 (d, J = 8.3 Hz, 1H, NH), 8.28 (br. s, 1H, NH), 7.99-7.97 (m, 1H, H_{arom.}), 7.92-7.88 (m, 2H, H_{arom.}), 7.60-7.54 (m, 5H, H_{arom.}), 7.42 (t, J = 9.0 Hz, 1H, H_{arom.}), 7.35 (dd, J = 2.5 Hz, 1H, H_{arom.}), 7.03 (d, J = 8.3 Hz, 1H, CH), 4.79

(q, $J = 15.5$ Hz, 2H, CH₂). ¹³C NMR: δ 182.8 (C=S), 166.7 (C=O), 152.3, 134.2, 133.9, 129.5, 129.4, 128.2, 128.0, 127.0, 126.4, 126.3, 125.6, 125.4, 125.1, 122.8, 122.6, 115.8 (C_{arom.}), 101.5 (CCl₃), 69.7 (CH), 67.7 (CH₂). Anal. Calcd (%) for C₂₁H₁₆Cl₅N₃O₂S (551.69): C, 45.72; H, 2.92; N, 7.62. Found: C, 45.70; H, 2.89; N, 7.65.

2.2. Molecular Docking Studies

Before molecular docking, the structures of the resulting thioureas **9a-h** and 2,4-dichlorophenoxyacetic acid were optimized. We used the semiempirical PM3 method [26] implemented in the ArgusLab 4.0.1 software package [27-31] for optimization.

The 3D structure of the COX-2 enzyme (PDB ID: 4M11, *Mus musculus*) was downloaded in PDB format from the Protein Data Bank [32]. The protein structure was prepared for docking using the Chimera 1.14 program [33]. Before docking, we removed water molecules and all non-amino acid components from the protein structure, except for hemes.


Molecular docking was carried out using AutoDock Vina [34], implemented on the PyRx 0.8 platform. The position of the inhibitor molecule in the active site of the enzyme with the lowest ΔG was taken as the most probable binding position. The docking area was centered on the amino acids Arg 120, Ser 353, Tyr 355, Tyr 385, Val 523, and Ser 530 [35]. The grid size was X: 25.0 Y: 25.0 Z: 25.0 Å and the coordinates of its center were X: 17.1 Y: 43.2 Z: 32.6. To visualize the results, we used the PyMOL 0.99rc6 program [36].

3. Results and Discussion

The starting materials for obtaining the target 2-(2,4-dichlorophenoxy)-*N*-(2,2,2-trichloro-1-(3-arylthioureido)ethyl)acetamides (**7a-h**) were synthesized according to previously developed procedures. 2-(2,4-Dichlorophenoxy)-*N*-(2,2,2-trichloro-1-hydroxyethyl)acetamide (**3**) was obtained by the condensation of chloral hydrate (**1**) with 2,4-dichlorophenoxyacetic acid amide (**2**) in the melt [24]. Next, the resulting compound **3** was chlorinated at the hydroxyl group, followed by the chlorine atom substitution in compound **4** for the isothiocyanate group according to the procedure described in [25]. Thioureas (**7a-h**) were obtained by the amines **6a-h** addition to 2-(2,4-dichlorophenoxy)-*N*-(2,2,2-trichloro-1-isothiocyanatoethyl)acetamide (**5**) in acetonitrile medium (Scheme 1).

The structure of thioureas **7a-h** was proved by ¹H and ¹³C NMR spectroscopy. In the ¹H NMR spectra, the signals of three NH protons were characteristic, which appeared in the region of 10.65–8.02 ppm. The CH signal of the proton located near the trichloromethyl group appeared as a doublet or doublet of doublets at 7.03–5.98 ppm. The signal of the methylene group of the 2,4-dichlorophenoxyacetic acid residue was also characteristic, which appeared in the region of 4.81–4.77 ppm in the form of a quartet with a spin-spin interaction constant of about 15.5 Hz. In the ¹³C NMR spectra, the signals of the carbons C=S, C=O, CCl₃, CH, and CH₂ groups were characteristic. The C=S signal of the carbon of the thiourea fragment was in the low-field region at 182.8–180.5 ppm. In turn, the carbon signal of the amide group appeared at about 166.7 ppm. The CCl₃, CH, and CH₂ group signals appeared at 101.6–101.0, 70.7–69.1, and 67.8–67.1 ppm, respectively.

The structures of all studied compounds effectively interacted with the COX-2 active site according to the results of molecular docking. The energy value of the COX-2:Ligand complex took from -10.4 to -8.9 kcal/mol. According to this parameter, thioureas **7a-h** were significantly superior to 2,4-dichlorophenoxyacetic acid, which we used as a reference compound. The energy value of the complex was -6.7 kcal/mol for 2,4-D. At the same time, the 2,4-dichlorophenoxyacetic acid molecule was effectively fixed in the COX-2 active site (Figure 2a) through the formation of two intermolecular hydrogen bonds, 3.0 and 3.2 Å long, with the amino acid Arg 120, and one hydrogen bond, 3.2 Å long, with Tyr 155 (for comparison, see [2]). Among the studied compounds, thiourea **7h** interacted most effectively with the COX-2 active site. This compound formed four intermolecular hydrogen bonds with amino acids of the active site, three of which, from 2.8 to 3.2 Å long, with Arg 120, and one, 3.1 Å long, with Tyr 355 (Figure 2b). The value of ΔG was -10.4 kcal/mol.



Scheme

1. Synthesis of 2-(2,4-dichlorophenoxy)-*N*-(2,2,2-trichloro-1-(3-arylthioureido)ethyl)acetamides (**7a-h**). Reagents and conditions: a) heating, solvent-free; b) SOCl₂, CCl₄, reflux 1.5 h; c) KSCN, MeCN, r.t., 24 h; d) MeCN, reflux 1 min then left at r.t. 24 h.




Figure 2. Molecule position of 2,4-dichlorophenoxyacetic acid (a) and 2-(2,4-dichlorophenoxy)-*N*-(2,2,2-trichloro-1-(3-(naphthalen-1-yl)thioureido)ethyl)acetamide (**7h**) (b) in the active site of COX-2 according to the results of molecular docking.

4. Conclusion

In this study, we have obtained a series of 2-(2,4-dichlorophenoxy)-*N*-(2,2,2-trichloro-1-(3-arylthioureido)ethyl)acetamides simultaneously containing 2,4-dichlorophenoxy, alkylamide and thiourea pharmacophore groups. The structures of the obtained compounds have been tested for the ability to inhibit the COX-2 enzyme using molecular docking. It has been shown that the test compounds are significantly superior to 2,4-dichlorophenoxyacetic acid in terms of the strength of the complex formed with this enzyme.

Supplementary Materials: The following supporting information can be downloaded at: www.mdpi.com/xxx/s1, Figure S1. ¹H NMR (400 MHz, DMSO-d₆) spectra of 2-(2,4-dichlorophenoxy)-*N*-(2,2,2-trichloro-1-(3-(2,4-dimethylphenyl)thioureido)ethyl)acetamide (**7a**); Figure S2. ¹³C NMR (100 MHz, DMSO-d₆) spectra of 2-(2,4-dichlorophenoxy)-*N*-(2,2,2-trichloro-1-(3-(2,4-dimethylphenyl)thioureido)ethyl)acetamide (**7a**); Figure S3. ¹H NMR (400 MHz, DMSO-d₆)

spectra of 2-(2,4-dichlorophenoxy)-*N*-(2,2,2-trichloro-1-(3-(2,5-dimethylphenyl)thioureido)ethyl)acetamide (**7b**); Figure S4. ¹³C NMR (100 MHz, DMSO-*d*₆) spectra of 2-(2,4-dichlorophenoxy)-*N*-(2,2,2-trichloro-1-(3-(2,5-dimethylphenyl)thioureido)ethyl)acetamide (**7b**); Figure S5. ¹H NMR (400 MHz, DMSO-*d*₆) spectra of 2-(2,4-dichlorophenoxy)-*N*-(2,2,2-trichloro-1-(3-(2-methoxyphenyl)thioureido)ethyl)acetamide (**7c**); Figure S6. ¹³C NMR (100 MHz, DMSO-*d*₆) spectra of 2-(2,4-dichlorophenoxy)-*N*-(2,2,2-trichloro-1-(3-(2-methoxyphenyl)thioureido)ethyl)acetamide (**7c**); Figure S7. ¹H NMR (400 MHz, DMSO-*d*₆) spectra of *N*-(1-(3-(4-acetamidophenyl)thioureido)-2,2,2-trichloroethyl)-2-(2,4-dichlorophenoxy)acetamide (**7d**); Figure S8. ¹³C NMR (100 MHz, DMSO-*d*₆) spectra of *N*-(1-(3-(4-acetamidophenyl)thioureido)-2,2,2-trichloroethyl)-2-(2,4-dichlorophenoxy)acetamide (**7d**); Figure S9. ¹H NMR (400 MHz, DMSO-*d*₆) spectra of ethyl 4-(3-(2,2,2-trichloro-1-(2-(2,4-dichlorophenoxy)acetamido)ethyl)thioureido)benzoate (**7e**); Figure S10. ¹³C NMR (100 MHz, DMSO-*d*₆) spectra of ethyl 4-(3-(2,2,2-trichloro-1-(2-(2,4-dichlorophenoxy)acetamido)ethyl)thioureido)benzoate (**7e**); Figure S11. ¹H NMR (400 MHz, DMSO-*d*₆) spectra of 2-(2,4-dichlorophenoxy)-*N*-(2,2,2-trichloro-1-(3-(2-chlorophenyl)thioureido)ethyl)acetamide (**7f**); Figure S12. ¹³C NMR (100 MHz, DMSO-*d*₆) spectra of 2-(2,4-dichlorophenoxy)-*N*-(2,2,2-trichloro-1-(3-(2-chlorophenyl)thioureido)ethyl)acetamide (**7f**); Figure S13. ¹H NMR (400 MHz, DMSO-*d*₆) spectra of *N*-(1-(3-(4-bromophenyl)thioureido)-2,2,2-trichloroethyl)-2-(2,4-dichlorophenoxy)acetamide (**7g**); Figure S14. ¹³C NMR (100 MHz, DMSO-*d*₆) spectra of *N*-(1-(3-(4-bromophenyl)thioureido)-2,2,2-trichloroethyl)-2-(2,4-dichlorophenoxy)acetamide (**7g**); Figure S15. ¹H NMR (400 MHz, DMSO-*d*₆) spectra of 2-(2,4-dichlorophenoxy)-*N*-(2,2,2-trichloro-1-(3-(naphthalen-1-yl)thioureido)ethyl)acetamide (**7h**); Figure S16. ¹³C NMR (100 MHz, DMSO-*d*₆) spectra of 2-(2,4-dichlorophenoxy)-*N*-(2,2,2-trichloro-1-(3-(naphthalen-1-yl)thioureido)ethyl)acetamide (**7h**).

Author Contributions: E.R.L.; methodology, formal analysis, investigation. P.V.Z.; conceptualization, methodology, writing-original draft, formal analysis, investigation, visualization, project administration. V.V.K.; methodology, formal analysis, investigation. V.V.K.; validation, resources, writing-review and editing. A.V.K.; validation, supervision, writing-review and editing.

Funding: The work has been carried out within the framework of the project "New principles of synthesis of fluorescent materials and biologically active *N,S*-containing heterocycles" (state registration number 0123U101168) funded by the Ministry of Education and Science of Ukraine.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

1. References

- Song, Y. Insight into the mode of action of 2,4-dichlorophenoxyacetic acid (2,4-D) as an herbicide. *J. Integr. Plant Biol.* **2014**, *56*, 106-113. <https://doi.org/10.1111/jipb.12131>
- Khedr, M.A.; Shehata, T.M.; Mohamed, M.E. Repositioning of 2,4-dichlorophenoxy acetic acid as a potential anti-inflammatory agent: *in silico* and pharmaceutical formulation study. *Eur. J. Pharm. Sci.* **2014**, *65*, 130-138. <https://doi.org/10.1016/j.ejps.2014.09.014>
- Ali, Y.; Alam, M.S.; Hamid, H.; Husain, A.; Dhulap, A.; Bano, S.; Kharbanda, C. Novel 2,4-dichlorophenoxy acetic acid substituted thiazolidin-4-ones as anti-inflammatory agents: Design, synthesis and biological screening. *Bioorg. Med. Chem. Lett.* **2017**, *27*, 1017-1025. <https://doi.org/10.1016/j.bmcl.2016.12.069>
- El Shehry, M.F.; Abu-Hashem, A.A.; El-Telbani, E.M. Synthesis of 3-((2,4-dichlorophenoxy)methyl)-1,2,4-triazolo(thiadiazoles and thiadiazines) as anti-inflammatory and molluscicidal agents. *Eur. J. Med. Chem.* **2010**, *45*, 1906-1911. <https://doi.org/10.1016/j.ejmech.2010.01.030>
- Atkinson, D.C.; Leach, E.C. Anti-inflammatory and related properties of 2-(2,4-dichlorophenoxy)phenylacetic acid (fenclofenac). *Agents Actions.* **1976**, *6*, 657-666. <https://doi.org/10.1007/BF01971587>
- Elufioye, T.O.; Habtemariam, S.; Adejare, A. Chemistry and Pharmacology of Alkylamides from Natural Origin. *Rev. Bras. Farmacogn.* **2020**, *30*, 622-640. <https://doi.org/10.1007/s43450-020-00095-5>
- Dallazen, J.L.; Maria-Ferreira, D.; da Luz, B.B.; Nascimento, A.M.; Cipriani, T.R.; de Souza, L.M.; Felipe, L.P.G.; Silva, B.J.G.; Nassini, R.; de Paula Werner, M.F. Pharmacological potential of alkylamides from *Acmella oleracea* flowers and synthetic isobutylalkyl amide to treat inflammatory pain. *Inflammopharmacology.* **2020**, *28*, 175-186. <https://doi.org/10.1007/s10787-019-00601-9>

8. Zadorozhnii, P.V.; Kiselev, V.V.; Teslenko, N.O.; Kharchenko, A.V.; Pokotylo, I.O.; Okhtina, O.V.; Kryshchych, O.V. *In Silico* Prediction and Molecular Docking Studies of *N*-Amidoalkylated Derivatives of 1,3,4-Oxadiazole as COX-1 and COX-2 Potential Inhibitors. *Res. J. Pharm. Technol.* **2017**, *10*, 3957–3963. <https://doi.org/10.5958/0974-360X.2017.00718.1>
9. Liu, R.; Caram-Salas, N.L.; Li, W.; Wang, L.; Arnason, J.T.; Harris, C.S. Interactions of *Echinacea* spp. Root Extracts and Alkylamides With the Endocannabinoid System and Peripheral Inflammatory Pain. *Front. Pharmacol.* **2021**, *12*, 651292. <https://doi.org/10.3389/fphar.2021.651292>
10. Nedeljković, N.; Dobričić, V.; Bošković, J.; Vesović, M.; Bradić, J.; Anđić, M.; Kočović, A.; Jeremić, N.; Novaković, J.; Jakovljević, V.; Vujić, Z.; Nikolić, M. Synthesis and Investigation of Anti-Inflammatory Activity of New Thiourea Derivatives of Naproxen. *Pharmaceuticals (Basel)*. **2023**, *16*, 666. <https://doi.org/10.3390/ph16050666>
11. Calixto, S.D.; Simão, T.L.B.V.; Palmeira-Mello, M.V.; Viana, G.M.; Assumpção, P.W.M.C.; Rezende, M.G.; do Espírito Santo, C.C.; de Oliveira Mussi, V.; Rodrigues, C.R.; Lasunskaja, E.; de Souza, A.M.T.; Cabral, L.M.; Muzitano, M.F. Antimycobacterial and anti-inflammatory activities of thiourea derivatives focusing on treatment approaches for severe pulmonary tuberculosis. *Bioorg. Med. Chem.* **2022**, *53*, 116506. <https://doi.org/10.1016/j.bmc.2021.116506>
12. Canatar, C.; Türkben, H.; Efeoglu, C.; Sari, H.; Karasu, E.; Nural, Y.; Ayaz, F. Anti-inflammatory Potential of 1,4-Naphthoquinone Acyl Thiourea Hybrids on Lipopolysaccharide-Activated Mammalian Macrophages, and Their Acid Dissociation Constants. *ChemistrySelect*. **2023**, *8*, e202301258. <https://doi.org/10.1002/slct.202301258>
13. Boyce, M.; Bryant, K.F.; Jousse, C.; Long, K.; Harding, H.P.; Scheuner, D.; Kaufman, R.J.; Ma, D.; Coen, D.M.; Ron, D.; et al. A Selective Inhibitor of eIF2 α Dephosphorylation Protects Cells from ER Stress. *Science* **2005**, *307*, 935–939. <https://doi.org/10.1126/science.1101902>
14. Long, K.; Boyce, M.; Lin, H.; Yuan, J.; Ma, D. Structure-activity relationship studies of salubrinal lead to its active biotinylated derivative. *Bioorg. Med. Chem. Lett.* **2005**, *15*, 3849–3852. <https://doi.org/10.1016/j.bmcl.2005.05.120>
15. Zadorozhnii, P.V.; Pokotylo, I.O.; Kiselev, V.V.; Okhtina, O.V.; Kharchenko, A.V. Molecular docking studies of salubrinal and its analogs as inhibitors of the GADD34:PP1 enzyme. *ADMET DMPK* **2019**, *7*, 140–150. <http://doi.org/10.5599/admet.632>
16. Liu, J.; He, K.L.; Li, X.; Li, R.J.; Liu, C.L.; Zhong, W.; Li, S. SAR, Cardiac Myocytes Protection Activity and 3D-QSAR Studies of Salubrinal and its Potent Derivatives. *Curr. Med. Chem.* **2012**, *19*, 6072–6079. <https://doi.org/10.2174/0929867311209066072>
17. Zadorozhnii, P.V.; Kiselev, V.V.; Kharchenko, A.V. *In Silico* ADME Profiling of Salubrinal and Its Analogues. *Future Pharmacol.* **2022**, *2*, 160–197. <https://doi.org/10.3390/futurepharmacol2020013>
18. Zadorozhnii, P.V.; Kiselev, V.V.; Kharchenko, A.V. *In silico* toxicity evaluation of Salubrinal and its analogues. *Eur. J. Pharm. Sci.* **2020**, *155*, 105538. <https://doi.org/10.1016/j.ejps.2020.105538>
19. Zadorozhnii, P.V.; Kiselev, V.V.; Pokotylo, I.O.; Kharchenko, A.V. A new method for the synthesis of 4*H*-1,3,5-oxadiazine derivatives. *Heterocycl. Commun.* **2017**, *23*, 369–374. <https://doi.org/10.1515/hc-2017-0083>
20. Zadorozhnii, P.V.; Kiselev, V.V.; Pokotylo, I.O.; Okhtina, O.V.; Kharchenko, A.V. Synthesis and mass spectrometric fragmentation pattern of 6-(4-chlorophenyl)-*N*-aryl-4-(trichloromethyl)-4*H*-1,3,5-oxadiazin-2-amines. *Heterocycl. Commun.* **2018**, *24*, 273–278. <https://doi.org/10.1515/hc-2018-0082>
21. Zadorozhnii, P.V.; Kiselev, V.V.; Hrek, O.O.; Kharchenko, A.V.; Okhtina, O.V. Synthesis, spectral characteristics, and molecular structure of 2-(2,4-dichlorophenyl)-6-(2-methoxybenzyl)-4-(trichloromethyl)-4*H*-1,3,5-oxadiazine. *Struct. Chem.* **2022**, *33*, 2127–2132. <https://doi.org/10.1007/s11224-022-02024-9>
22. Lominoga, E.R.; Zadorozhnii, P.V.; Kiselev, V.V.; Kharchenko, A.V. Synthesis of 6-(4-Chlorophenyl)-*N*-aryl-4-(trichloromethyl)-4*H*-1,3,5-oxadiazin-2-amines: A Comparative Evaluation of Dehydrosulfurization Methods of Starting 4-Chloro-*N*-(2,2,2-trichloro-1-(3-arylthioureido)ethyl)benzamides. *Chem. Proc.* **2022**, *12*, 58. <https://doi.org/10.3390/ecsoc-26-13538>
23. Gaitandjiev, S. β , β , β -Trichloro- α -hydroxyethylamides of some chlorinated phenoxyacetic acids. *Dokl. Bulg. Acad. Nauk.* **1963**, *16*, 45–48.
24. Pokotylo, I.O.; Zadorozhnii, P.V.; Kiselev, V.V.; Kharchenko, A.V. Solvent-free synthesis and spectral characteristics of *N*-(2,2,2-trichloro-1-hydroxyethyl)carboxamides. *Chem. Data Coll.* **2018**, *15*–*16*, 62–66. <https://doi.org/10.1016/j.cdc.2018.04.002>
25. Zadorozhnii, P.V.; Pokotylo, I.O.; Kiselev, V.V.; Kharchenko, A.V.; Okhtina, O.V. Synthesis and spectral characteristics of *N*-(1-([1,2,4]triazolo[3,4-*b*][1,3,4]thiadiazol-6-ylamino)-2,2,2-trichloroethyl)carboxamides. *Heterocycl. Commun.* **2019**, *25*, 130–137. <https://doi.org/10.1515/hc-2019-0020>
26. Thiel, W. Semiempirical quantum-chemical methods. *Wiley Interdiscip. Rev. Comput. Mol. Sci.* **2014**, *4*, 145–157. <https://doi.org/10.1002/wcms.1161>
27. Thompson, M.A.; Zerner, M.C. A theoretical examination of the electronic structure and spectroscopy of the photosynthetic reaction center from *Rhodospseudomonas viridis*. *J. Am. Chem. Soc.* **1991**, *113*, 8210–8215. <https://doi.org/10.1021/ja00022a003>
28. Thompson, M.A.; Glendening, E.D.; Feller, D. The Nature of K⁺/Crown Ether Interactions: A Hybrid Quantum Mechanical-Molecular Mechanical Study. *J. Phys. Chem.* **1994**, *98*, 10465–10476. <https://doi.org/10.1021/j100092a015>
29. Thompson, M.A.; Schenter, G.K. Excited States of the Bacteriochlorophyll *b* Dimer of *Rhodospseudomonas viridis*: A QM/MM Study of the Photosynthetic Reaction Center That Includes MM Polarization. *J. Phys. Chem.* **1995**, *99*, 6374–6386. <https://doi.org/10.1021/j100017a017>
30. Thompson, M.A. QM/MMpol: A Consistent Model for Solute/Solvent Polarization. Application to the Aqueous Solvation and Spectroscopy of Formaldehyde, Acetaldehyde, and Acetone. *J. Phys. Chem.* **1996**, *100*, 14492–14507. <https://doi.org/10.1021/jp960690m>

31. Thompson, M. *ArgusLab 4.0.1*; Planaria software LLC: Seattle, WA, USA, 2004. Available online: <http://www.arguslab.com> (accessed on 30th august 2023)
32. wwPDB consortium. Protein Data Bank: the single global archive for 3D macromolecular structure data. *Nucleic Acids Res.* **2019**, *47*, D520-D528. <https://doi.org/10.1093/nar/gky949>
33. Pettersen, E.F.; Goddard, T.D.; Huang, C.C.; Couch, G.S.; Greenblatt, D.M.; Meng, E.C.; Ferrin, T.E. UCSF Chimera - A visualization system for exploratory research and analysis. *J. Comput. Chem.* **2004**, *25*, 1605–1612. <https://doi.org/10.1002/jcc.20084>
34. Trott, O.; Olson, A.J. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading. *J. Comput. Chem.* **2010**, *31*, 455–461. <https://doi.org/10.1002/jcc.21334>
35. Świątek, P.; Gębczak, K.; Gębarowski, T.; Urniaz, R. Biological Evaluation and Molecular Docking Studies of Dimethylpyridine Derivatives. *Molecules* **2019**, *24*, 1093. <https://doi.org/10.3390/molecules24061093>
36. DeLano, W.L. *The PyMOL Molecular Graphics System*; DeLano Scientific: Palo Alto, CA, USA, 2003. Available online: <http://www.pymol.org> (accessed on 27 august 2015)